Clinical and Radiological Features of COPD Patients Living at ≥3000 m Above Sea Level in the Tibet Plateau

References

• Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease, 2021 report. Available from: http://www.goldcopd.org/. Accessed January 15, 2021.
   Google Scholar
• Soriano JB, Abajobir AA, Abate KH; GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med. 2017;5(9):691–706. doi:10.1016/S2213-2600(17)30293-X
   PubMed Web of Science ®Google Scholar
• Wang C, Xu J, Yang L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study. Lancet. 2018;391(10131):1706–1717. doi:10.1016/S0140-6736(18)30841-9
   PubMed Web of Science ®Google Scholar
• Khakban A, Sin DD, FitzGerald JM, et al. Ten-year trends in direct costs of COPD: a population-based study. Chest. 2015;148(3):640–646. doi:10.1378/chest.15-0721
   PubMed Web of Science ®Google Scholar
• Cohen JE, Small C. Hypsographic demography: the distribution of human population by altitude. Proc Natl Acad Sci USA. 1998;95(24):14009–14014. doi:10.1073/pnas.95.24.14009
   PubMed Web of Science ®Google Scholar
• Burtscher M. Effects of living at higher altitudes on mortality: a narrative review. Aging Dis. 2014;5(4):274–280. doi:10.14336/AD.2014.0500274
   PubMed Web of Science ®Google Scholar
• Ezzati M, Horwitz ME, Thomas DS, et al. Altitude, life expectancy and mortality from ischaemic heart disease, stroke, COPD and cancers: national population-based analysis of US counties. J Epidemiol Community Health. 2012;66(7):e17. doi:10.1136/jech.2010.112938
   PubMed Web of Science ®Google Scholar
• Pierson DJ. Pathophysiology and clinical effects of chronic hypoxia. Respir Care. 2000;45(1):39–51; discussion 51–53.
   Google Scholar
• Guo Y, Xing Z, Shan G, et al. Prevalence and risk factors for COPD at high altitude: a large cross-sectional survey of subjects living between 2100–4700 m above sea level. Front Med (Lausanne). 2020;7:581763. doi:10.3389/fmed.2020.581763
   PubMed Web of Science ®Google Scholar
• van Gemert F, Kirenga B, Chavannes N, et al. Prevalence of chronic obstructive pulmonary disease and associated risk factors in Uganda (FRESH AIR Uganda): a prospective cross-sectional observational study. Lancet Glob Health. 2015;3(1):e44–e51. doi:10.1016/S2214-109X(14)70337-7
   PubMed Web of Science ®Google Scholar
• Brakema EA, Tabyshova A, Kasteleyn MJ, et al. High COPD prevalence at high altitude: does household air pollution play a role. Eur Respir J. 2019;53(2):1801193. doi:10.1183/13993003.01193-2018
   PubMed Web of Science ®Google Scholar
• Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD assessment test. Eur Respir J. 2009;34(3):648–654. doi:10.1183/09031936.00102509
   PubMed Web of Science ®Google Scholar
• Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J. 2005;26(2):319–338. doi:10.1183/09031936.05.00034805
   PubMed Web of Science ®Google Scholar
• Wang Z, Gu S, Leader JK, et al. Optimal threshold in CT quantification of emphysema. Eur Radiol. 2013;23(4):975–984. doi:10.1007/s00330-012-2683-z
   PubMed Web of Science ®Google Scholar
• Occhipinti M, Paoletti M, Bartholmai BJ, et al. Spirometric assessment of emphysema presence and severity as measured by quantitative CT and CT-based radiomics in COPD. Respir Res. 2019;20(1):101. doi:10.1186/s12931-019-1049-3
   PubMedGoogle Scholar
• Occhipinti M, Paoletti M, Crapo JD, et al. Validation of a method to assess emphysema severity by spirometry in the COPDGene study. Respir Res. 2020;21(1):103. doi:10.1186/s12931-020-01366-4
   PubMed Web of Science ®Google Scholar
• Gu S, Fuhrman C, Meng X, et al. Computerized identification of airway wall in CT examinations using a 3D active surface evolution approach. Med Image Anal. 2013;17(3):283–296. doi:10.1016/j.media.2012.11.003
   PubMed Web of Science ®Google Scholar
• Han MK, Kazerooni EA, Lynch DA, et al. Chronic obstructive pulmonary disease exacerbations in the COPDGene study: associated radiologic phenotypes. Radiology. 2011;261(1):274–282. doi:10.1148/radiol.11110173
   PubMed Web of Science ®Google Scholar
• Bai Y, Wang X, Lin F, Liao Y, Tao L, Chen Y. [Quantitative study on HRCT phenotype of the GOLD COPD assessment staging system]. Zhonghua Jie He He Hu Xi Za Zhi. 2015;38(5):356–360. Chinese. doi:10.3760/cma.j.issn.1001-0939.2015.05.009
   PubMedGoogle Scholar
• Niimi A, Matsumoto H, Amitani R, et al. Airway wall thickness in asthma assessed by computed tomography. Relation to clinical indices. Am J Respir Crit Care Med. 2000;162(4):1518–1523. doi:10.1164/ajrccm.162.4.9909044
   PubMed Web of Science ®Google Scholar
• Subramanian DR, Gupta S, Burggraf D, et al. Emphysema- and airway-dominant COPD phenotypes defined by standardised quantitative computed tomography. Eur Respir J. 2016;48(1):92–103. doi:10.1183/13993003.01878-2015
   PubMed Web of Science ®Google Scholar
• Jin J, Yu W, Li S, Lu L, Liu X, Sun Y. Factors associated with bronchiectasis in patients with moderate-severe chronic obstructive pulmonary disease. Medicine (Baltimore). 2016;95(29):e4219. doi:10.1097/MD.0000000000004219
   PubMed Web of Science ®Google Scholar
• Liang Y, Chen Y, Wu R, et al. Chronic bronchitis is associated with severe exacerbation and prolonged recovery period in Chinese patients with COPD: a multicenter cross-sectional study. J Thorac Dis. 2017;9(12):5120–5130. doi:10.21037/jtd.2017.11.54
   PubMed Web of Science ®Google Scholar
• Jin J, Li S, Yu W, Liu X, Sun Y. Emphysema and bronchiectasis in COPD patients with previous pulmonary tuberculosis: computed tomography features and clinical implications. Int J Chron Obstruct Pulmon Dis. 2018;13:375–384. doi:10.2147/COPD.S152447
   PubMed Web of Science ®Google Scholar
• Liang Y, Chang C, Chen Y, Dong F, Zhang L, Sun Y. Symptoms, management and healthcare utilization of COPD patients during the COVID-19 epidemic in Beijing. Int J Chron Obstruct Pulmon Dis. 2020;15:2487–2494. doi:10.2147/COPD.S270448
   PubMed Web of Science ®Google Scholar
• Zhong N, Wang C, Yao W, et al. Prevalence of chronic obstructive pulmonary disease in China: a large, population-based survey. Am J Respir Crit Care Med. 2007;176(8):753–760. doi:10.1164/rccm.200612-1749OC
   PubMed Web of Science ®Google Scholar
• Hu G, Zhou Y, Tian J, et al. Risk of COPD from exposure to biomass smoke: a meta analysis. Chest. 2010;138(1):20–31. doi:10.1378/chest.08-2114
   PubMed Web of Science ®Google Scholar
• Nicolaou L, Checkley W. Differences between cigarette smoking and biomass smoke exposure: an in silico comparative assessment of particulate deposition in the lungs. Environ Res. 2021;197:111116. doi:10.1016/j.envres.2021.111116
   PubMed Web of Science ®Google Scholar
• Zhou Y, Zou Y, Li X, et al. Lung function and incidence of chronic obstructive pulmonary disease after improved cooking fuels and kitchen ventilation: a 9-year prospective cohort study. PLoS Med. 2014;11(3):e1001621. doi:10.1371/journal.pmed.1001621
   PubMed Web of Science ®Google Scholar
• Vogelmeier C, Hederer B, Glaab T, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med. 2011;364(12):1093–1103. doi:10.1056/NEJMoa1008378
   PubMed Web of Science ®Google Scholar
• Decramer ML, Chapman KR, Dahl R, et al. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. Lancet Respir Med. 2013;1(7):524–533. doi:10.1016/S2213-2600(13)70158-9
   PubMed Web of Science ®Google Scholar
• Karner C, Chong J, Poole P. Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014;(7):CD009285. doi:10.1002/14651858.CD009285.pub3
   PubMed Web of Science ®Google Scholar
• Orlandi I, Moroni C, Camiciottoli G, et al. Chronic obstructive pulmonary disease: thin-section CT measurement of airway wall thickness and lung attenuation. Radiology. 2005;234(2):604–610. doi:10.1148/radiol.2342040013
   PubMed Web of Science ®Google Scholar
• Lim JU, Kim EK, Lim SY, et al. Mixed phenotype of emphysema and airway wall thickening is associated with frequent exacerbation in chronic obstructive pulmonary disease patients. Int J Chron Obstruct Pulmon Dis. 2019;14:3035–3042. doi:10.2147/COPD.S227377
   PubMed Web of Science ®Google Scholar
• Byrne AL, Marais BJ, Mitnick CD, Lecca L, Marks GB. Tuberculosis and chronic respiratory disease: a systematic review. Int J Infect Dis. 2015;32:138–146. doi:10.1016/j.ijid.2014.12.016
   PubMed Web of Science ®Google Scholar
• Ravimohan S, Kornfeld H, Weissman D, Bisson GP. Tuberculosis and lung damage: from epidemiology to pathophysiology. Eur Respir Rev. 2018;27:147. doi:10.1183/16000617.0077-2017
   Web of Science ®Google Scholar
• Fan H, Wu F, Liu J, et al. Pulmonary tuberculosis as a risk factor for chronic obstructive pulmonary disease: a systematic review and meta-analysis. Ann Transl Med. 2021;9(5):390. doi:10.21037/atm-20-4576
   PubMed Web of Science ®Google Scholar
• Horner A, Soriano JB, Puhan MA, et al. Altitude and COPD prevalence: analysis of the PREPOCOL-PLATINO-BOLD-EPI-SCAN study. Respir Res. 2017;18(1):162. doi:10.1186/s12931-017-0643-5
   PubMedGoogle Scholar